Table 1 Patient characteristics Patient... | American Society of Hematology

Table 1

Patient characteristics

Patient no.	Age, y	Sex	Time since diagnosis, y	Time since cladribine, y	Treatment before cladribine	CBC before cladribine				Current CBC				Bone marrow studies
Patient no.	Age, y	Sex	Time since diagnosis, y	Time since cladribine, y	Treatment before cladribine	WBC, × 10⁹/L	ANC, × 10⁹/L	Hemoglobin, g/L	Platelets, × 10⁹/L	WBC, × 10⁹/L	ANC, × 10⁹/L	Hemoglobin, g/L	Platelets, 10⁹/L	Bone marrow status	IHC, percentage	FC, percentage
1	77	Male	22	17	S	5.9	0.7	89	112	9.2	3.3	153	238	MRD⁻	−	ND/PCR⁻
2	70	Female	16	16	None	1.6	0.8	78	126	7.5	5.8	137	244	MRD⁻	−	ND/PCR⁻
3	78	Male	20	15	I	1.9	1.2	145	56	10.8	8.2	140	323	MRD⁻	−	−
4	76	Male	25	16	None	2.5	1.4	116	87	4.6	2.8	124	162	MRD⁻	−	−
5	79	Male	16	16	None	2	0.4	126	60	4.2	2.6	131	150	MRD⁻	−	−
6	68	Male	23	17	S	2.5	0.4	101	112	6	3.2	150	293	MRD⁻	−	−
7	56	Female	16	16	None	2.1	0.7	108	92	6	3.8	138	339	MRD⁻	−	−
8	81	Female	19	16	None	8	0.2	102	80	8.6	7.3	113	125	MRD⁻	−	−
9	75	Male	17	17	None	4.1	2.5	137	67	14.9	13.3	121	176	MRD⁻	−	−
10	59	Female	16	15	I	1.8	0.8	123	80	5.9	2.7	142	246	MRD⁺	2-3	0.30
11	71	Male	18	16	I	1.7	0.6	144	105	5.5	3.9	173	158	MRD⁺	3-5	0.60
12	80	Male	20	17	None	1.4	0.6	150	68	3.6	2.3	149	136	MRD⁺	3-5	3
13	61	Male	18	16	None	11.7	1.6	111	81	6.5	5.3	136	230	MRD⁺	1	0.50
14	86	Male	12	11	None	2.9	1.1	138	90	6	3.9	142	281	MRD⁺	3	0.50
15	81	Male	20	17	S	25.4	2	103	141	7.9	4.1	165	224	MRD⁺	3-5	0.90
16	79	Male	16	16	None	1.7	0.3	108	51	7.4	6	131	240	MRD⁺	2-3	+
17	57	Male	17	17	None	1.7	0.2	122	53	4.3	2.5	165	125	GM⁺	20	0.50
18	67	Male	28	21	S	7.1	1	103	162	8.9	5.3	149	321	GM⁺	35	−
19	67	Male	18	16	I, O	1.9	0.7	130	120	3.4	1.9	142	183	GM⁺	50	3.00
Median	75		18	16		2.1	0.7	116	87	6	3.9	142	230

Patient no.	Age, y	Sex	Time since diagnosis, y	Time since cladribine, y	Treatment before cladribine	CBC before cladribine				Current CBC				Bone marrow studies
Patient no.	Age, y	Sex	Time since diagnosis, y	Time since cladribine, y	Treatment before cladribine	WBC, × 10⁹/L	ANC, × 10⁹/L	Hemoglobin, g/L	Platelets, × 10⁹/L	WBC, × 10⁹/L	ANC, × 10⁹/L	Hemoglobin, g/L	Platelets, 10⁹/L	Bone marrow status	IHC, percentage	FC, percentage
1	77	Male	22	17	S	5.9	0.7	89	112	9.2	3.3	153	238	MRD⁻	−	ND/PCR⁻
2	70	Female	16	16	None	1.6	0.8	78	126	7.5	5.8	137	244	MRD⁻	−	ND/PCR⁻
3	78	Male	20	15	I	1.9	1.2	145	56	10.8	8.2	140	323	MRD⁻	−	−
4	76	Male	25	16	None	2.5	1.4	116	87	4.6	2.8	124	162	MRD⁻	−	−
5	79	Male	16	16	None	2	0.4	126	60	4.2	2.6	131	150	MRD⁻	−	−
6	68	Male	23	17	S	2.5	0.4	101	112	6	3.2	150	293	MRD⁻	−	−
7	56	Female	16	16	None	2.1	0.7	108	92	6	3.8	138	339	MRD⁻	−	−
8	81	Female	19	16	None	8	0.2	102	80	8.6	7.3	113	125	MRD⁻	−	−
9	75	Male	17	17	None	4.1	2.5	137	67	14.9	13.3	121	176	MRD⁻	−	−
10	59	Female	16	15	I	1.8	0.8	123	80	5.9	2.7	142	246	MRD⁺	2-3	0.30
11	71	Male	18	16	I	1.7	0.6	144	105	5.5	3.9	173	158	MRD⁺	3-5	0.60
12	80	Male	20	17	None	1.4	0.6	150	68	3.6	2.3	149	136	MRD⁺	3-5	3
13	61	Male	18	16	None	11.7	1.6	111	81	6.5	5.3	136	230	MRD⁺	1	0.50
14	86	Male	12	11	None	2.9	1.1	138	90	6	3.9	142	281	MRD⁺	3	0.50
15	81	Male	20	17	S	25.4	2	103	141	7.9	4.1	165	224	MRD⁺	3-5	0.90
16	79	Male	16	16	None	1.7	0.3	108	51	7.4	6	131	240	MRD⁺	2-3	+
17	57	Male	17	17	None	1.7	0.2	122	53	4.3	2.5	165	125	GM⁺	20	0.50
18	67	Male	28	21	S	7.1	1	103	162	8.9	5.3	149	321	GM⁺	35	−
19	67	Male	18	16	I, O	1.9	0.7	130	120	3.4	1.9	142	183	GM⁺	50	3.00
Median	75		18	16		2.1	0.7	116	87	6	3.9	142	230

CBC indicates complete blood count; WBC, white blood cell count; ANC, absolute neutrophil count; S, splenectomy; I, interferon; O, other; IHC, anti-CD20 antibody; FC, flow cytometry; ND, not done; GM⁺, hairy cell morphology positive by hematoxylin and eosin stain; and −, negative.

View Large

This Feature Is Available To Subscribers Only